Core Insights - Fortrea Holdings Inc. (NASDAQ:FTRE) is recognized as one of the most promising small-cap stocks by Wall Street analysts [1] - The company has provided financial guidance for 2026, projecting total revenues between $2,550 million and $2,650 million, with adjusted EBITDA expected to range from $190 million to $220 million [4][6] Financial Performance - For Q4 2025, Fortrea reported sales of $660.5 million, while the total sales for the entire year reached $2,723.4 million [5] - The company experienced a GAAP net loss of $(986.2) million, primarily due to a $797.9 million non-cash goodwill impairment, although adjusted net income was reported at $40.4 million [5] - The adjusted EBITDA for 2025 was $189.9 million, and the company ended the year with $174.6 million in cash and cash equivalents, alongside $1,066.3 million in gross debt [5] Market Position - Fortrea Holdings operates as a global contract research organization, providing a range of services including clinical development, trial management, pharmacology, and consulting to pharmaceutical, biotech, and medical device companies [7]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K __________________________________ (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission file number 001-41704 __________________________________ Fortrea Holdings Inc. (Exac ...

Fortrea Holdings Inc. (FTRE) came out with quarterly earnings of $0.09 per share, missing the Zacks Consensus Estimate of $0.16 per share. This compares to earnings of $0.18 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -42.82%. A quarter ago, it was expected that this company would post earnings of $0.16 per share when it actually produced earnings of $0.12, delivering a surprise of -25%.Over the last four quarters, the com ...

Fortrea (NasdaqGS:FTRE) Q4 2025 Earnings call February 26, 2026 08:00 AM ET Company ParticipantsAnshul Thakral - CEO and DirectorDavid Windley - Managing DirectorElizabeth Anderson - Senior Managing DirectorJailendra Singh - Managing DirectorJill McConnell - CFOTracy Krumme - SVP of Investor RelationsConference Call ParticipantsAnn Hynes - AnalystEric Coldwell - Senior Research AnalystJustin Bowers - Biopharma Services Senior Equity Research AnalystMax Smock - AnalystPatrick Donnelly - Managing Director and ...

Fortrea (NasdaqGS:FTRE) Q4 2025 Earnings call February 26, 2026 08:00 AM ET Company ParticipantsAnshul Thakral - CEO and DirectorDavid Windley - Managing DirectorElizabeth Anderson - Senior Managing DirectorJailendra Singh - Managing DirectorJill McConnell - CFOTracy Krumme - SVP of Investor RelationsConference Call ParticipantsAnn Hynes - AnalystEric Coldwell - Senior Research AnalystJustin Bowers - Biopharma Services Senior Equity Research AnalystMax Smock - AnalystPatrick Donnelly - Managing Director and ...

Fortrea (NasdaqGS:FTRE) Q4 2025 Earnings call February 26, 2026 08:00 AM ET Speaker9Good day. Thank you for standing by. Welcome to the Fortrea Q4 and full year 2025 earnings conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during the session, you will need to press star one one on your telephone. You will hear an automated message advising your hand is raised. To withdraw your question ...

Learn more at fortrea.com. ©2026 Fortrea Inc. All rights reserved. Fortrea Q4'2025 Earnings presentation Q4 & FY 2025 Earnings Presentation 02.26.2026 Nasdaq: FTRE Learn more at fortrea.com. ©2026 Fortrea Inc. All rights reserved. Fortrea Q4'2025 Earnings presentation FORWARD-LOOKING STATEMENTS & NON-GAAP FINANCIAL MEASURES Forward-Looking Statements Disclosure. Certain information in this presentation contains "forward-looking" statements. You should not place undue reliance on these statements. Forward- l ...

Exhibit 99.1 Fortrea Reports Fourth Quarter and Full-Year 2025 Results; Issues Full-Year 2026 Guidance Revenue and Adjusted EBITDA results delivered in line with stated full-year targets Full ‑ year cost savings exceeded previously communicated targets Highlights: DURHAM, N.C., February 26, 2026 — Fortrea (Nasdaq: FTRE) (the "Company"), a leading global contract research organization (CRO), today reported financial results for the fourth quarter and full year ended December 31, 2025. "We finished 2025 with ...

Core Insights - Fortrea reported solid financial results for the fourth quarter and full year ended December 31, 2025, with a focus on operational excellence and positive client feedback [2][3] - The company aims to return to growth and margin expansion in 2026, targeting revenues between $2,550 million and $2,650 million and adjusted EBITDA between $190 million and $220 million [12] Fourth Quarter 2025 Financial Results - Revenue for the fourth quarter was $660.5 million, a decrease from $697.0 million in the fourth quarter of 2024 [4] - GAAP net loss for the fourth quarter was $(32.5) million, or $(0.35) per diluted share, compared to a loss of $(73.9) million, or $(0.82) per diluted share in the same quarter of 2024 [5] - Adjusted net income for the fourth quarter was $9.2 million, or $0.09 per diluted share, down from $16.6 million, or $0.18 per diluted share in the fourth quarter of 2024 [5][10] - Adjusted EBITDA for the fourth quarter was $54.0 million, compared to $56.0 million in the fourth quarter of 2024 [5][10] - The book-to-bill ratio for the fourth quarter was 1.14x, contributing to a trailing twelve-month book-to-bill ratio of 1.02x [6][10] Full Year 2025 Financial Results - Total revenue for the full year was $2,723.4 million, slightly up from $2,696.4 million in 2024 [7] - Full year GAAP net loss was $(986.2) million, or $(10.81) per diluted share, which included a non-cash goodwill impairment charge of $797.9 million [8] - Adjusted net income for the full year was $40.4 million, or $0.43 per diluted share, compared to $30.1 million, or $0.33 per diluted share in 2024 [8][10] - Adjusted EBITDA for the full year was $189.9 million, down from $202.5 million in 2024 [8][10] Balance Sheet and Cash Flow - As of December 31, 2025, cash and cash equivalents were $174.6 million, with gross debt at $1,066.3 million [11] - Operating cash flow for the full year was $113.5 million, and free cash flow was $88.3 million [11][42] 2026 Financial Guidance - The company projects revenues for 2026 to be in the range of $2,550 million to $2,650 million and adjusted EBITDA between $190 million and $220 million [12]

此举旨在加强高管团队对早期临床开发的关注，并深化与客户的医疗和科学合作北卡罗来纳州达勒姆, Feb. 18, 2026 (GLOBE NEWSWIRE) -- 全球领先的合同研究组织 (CRO) Fortrea (Nasdaq: FTRE)（以下简称“公司”）今日宣布扩充其高管团队。此前兼任 Fortrea 首席医疗官 (CMO) 和临床药理服务 (CPS) 总裁的 Oren Cohen 医学博士，现专注于其 CMO 职责，主要负责 Fortrea 所有业务的医疗战略、科学领导、伦理和治理监督。Scott Dove 博士加入 Fortrea，担任临床药学服务总裁，负责 Fortrea 在其全球临床研究机构网络中的早期临床开发解决方案。Cohen 和 Dove 均是 Fortrea 的执行委员会成员。 首席执行官 Anshul Thakral 表示：“Scott 加入 Fortrea 团队，同时 Oren 完全专注于开发过程中的医学与科学事务，这对客户而言是一项双赢举措。Oren 将与我们在临床开发各阶段的业务负责人紧密协作，深化其与客户的关系。他更早地参与科学研讨，与公司医师及治疗领域领导者密切协作，共同应对 ...